A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Anti-CD19/CD22 chimeric antigen receptor T cell therapy Shenzhen BinDeBio (Primary)
- Indications B-cell lymphoma; Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Shenzhen BinDeBio
Most Recent Events
- 24 Dec 2019 New trial record